DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Ajanta Pharma Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·7 Oct 2026, 8:26 am

Ajanta Pharma

Ajanta Pharma has informed stock exchanges that it has received a certificate under SEBI's regulations regarding depositories and participants. This regulatory filing confirms the company's compliance with specific listing requirements. It is a standard administrative update that verifies the proper maintenance of the company's securities with the relevant depositories.

For investors, this news is largely procedural and does not signal any operational changes or financial performance shifts. It ensures that the company's shares remain eligible for trading on the stock market without interruption. The filing is a routine part of corporate governance for listed entities.

Investors should monitor the company's future quarterly results and product pipeline for more significant market-moving updates. This regulatory compliance is a baseline requirement and should not be viewed as a primary driver for investment decisions.